|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.390 USD | -0.88% |
|
-2.02% | +23.27% |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 386.6 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 89.12% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 199.5 | 74.31 | 200 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 225.65% | -62.75% | 169.08% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -3.06x | -2.99x | -3.18x |
| PBR | - | - | - | 0.78x | 0.99x | 1.5x | 1.29x | 1.8x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -1.37x | 0.54x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 925x | 793x | 28.7x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 478x | 152x | 14.8x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.57x | -0.52x | -1.31x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.59x | -0.51x | -1.38x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.91x | -0.54x | -1.33x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -52.3% | -187% | -75.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.109 | -1.134 | -1.066 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.4177 | 0.4875 | 13.49 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -126.9 | -144.2 | -153 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -125.4 | -144.8 | -144.5 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -121 | -138.1 | -137 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -187.1 | -312.3 | -186.7 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 3.390 | 3.390 | 3.390 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 114,046 | - | - |
| Announcement Date | 21/09/21 | 01/05/23 | 28/03/24 | 26/03/25 | 16/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.08x | 485.75x | -1.6x | -.--% | 390M | |
| 34.53x | 6.07x | 18.77x | 0.95% | 49.74B | |
| -23.85x | 349.22x | -22.56x | -.--% | 40.49B | |
| 25.34x | 2.8x | 12.11x | -.--% | 34.75B | |
| 47.3x | 4.68x | 29.91x | -.--% | 34.35B | |
| 27.63x | 7.94x | 19.87x | 0.41% | 26.98B | |
| 32.22x | 5.2x | 23.7x | -.--% | 15.6B | |
| -24.06x | 15.69x | -23.46x | -.--% | 14.27B | |
| 23.93x | 2.04x | 8.96x | 1.12% | 13.76B | |
| Average | 15.55x | 97.71x | 7.30x | 0.27% | 25.59B | |
| Weighted average by Cap. | 19.49x | 67.02x | 9.39x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
